Surgery of focal liver lesions in children: conserving surgery or transplantation?
Abstract
Hepatic tumors account for 1–4% of the solid tumors in children.
Aim. Results of surgery treatment assessment for pediatric liver tumors.
Material and methods. From April 2008 to December 2016, 97 pediatric patients (2 months –
17 years old) (median – 23.7; 25th and 75th quartiles – 13–80 months) with a variety of focal liver lesions underwent surgery at Petrovsky National Research Center of Surgery. Malignant tumors (n=74;
76.3%) were presented by hepatoblastoma (n=65; 67%), hepatocellular carcinoma (n=3; 3%), undifferentiated (embryonal) sarcoma (n=2; 2%), malignant rhabdoid tumor (n=2; 2%) and rhabdomyosarcoma (n=2; 2%). Benign lesions or neoplasms (n=23; 23.7%) were presented by focal nodular hyperplasia (n=7; 8%), mesenhymal hamartoma (n=5; 5%), hepatocellular adenoma (n=3; 3%),
infantile hemangioendothelioma (n=2; 2%), benign teratoma (n=2; 2%), cavernous hemangioma
(n=1; 1%), inflammatory pseudotumor (n=1; 1%). Two patients (2%) had a parasitic liver disease:
cystic and alveolar echinococcosis. Among the revealed tumors predominated hepatoblastoma.
Results. Patients with hepatoblastoma were classified according to PRETEXT system: PRETEXT I –
5% (n=3), PRETEXT II – 40% (n=26), PRETEXT III – 29% (n=19), PRETEXT IV – 26% (n=17).
In 15 children (23.1%) detected lung metastases. Neoadjuvant chemotherapy was performed
in 62 cases (95.4%). 8 patients (12.9%) had tumor regression with reduction of the tumor stage,
and 6 (9.7%) had increase in tumor progression. Due to the remote metastases in 7 cases lung
surgery was performed. Surgical treatment of hepatoblastoma included anatomical resection
(lobe- and extended lobectomies – 81.5% (n=53), bisegmentectomies – 6.2% (n=4), and living-donor liver transplantations – 12.3% (n=8). All resections were performed without clamping hepatoduodenal ligament. The volume of blood loss in patients with resection was 15.56±14.00 ml/kg.
Tumor free resection edge (R0 resection) was microscopically confirmed in all cases. In the group
of malignant tumors hospital mortality was 1% (n=1). The actuarial survival rate (total/recurrence-free) of all patients with hepatoblastoma was, respectively: 1 year 0.95±0.03/0.83±0.05;
3 years 0.88±0.05/0.81±0.05; 5 years 0.88±0.04/0.81±0.05; 7 years 0.88±0.05/0.81±0.05. In patients after resection corresponding figures were higher: 1 year 0.96±0.02/0.88±0.04; 3 years
0.89±0.05/0.86±0.05; 5 years 0.89±0.05/0.86±0.05; 7 years 0.89±0.05/0.86±0.05. In the group
with other forms of liver malignancies 2 of 9 patients died in the period from 2 to 30 months due to
the initial disease relapse. In groups of benign and parasitic diseases there were no deaths.
Conclusion. Surgical methods occupy a leading position in the radical treatment of both benign and malignant focal lesions of liver in children. Long-term results with high survival rates
for combined treatment of hepatoblastoma demonstrate broad opportunities for both resection
and liver transplantation under condition if optimal chemotherapy protocols are being selected.
Keywords:focal liver lesions, hepatoblastoma, anatomical resection, liver transplantation, pediatric
Clin. Experiment. Surg. Petrovsky J. 2017; 5 (1): 22–30.
DOI: 10.24411/2308-1198-2017-00016
Received: 15.12.2016. Accepted: 02.02.2017.
References
1. Zimmermann A., Perilongo G. Pediatric Liver Tumors. Heidelberg; Dordrecht; London; New York: Springer, 2011.
2. Stiller C., Pritchard J., Steliorova-Foucher E. Liver cancer in European children: incidence and survival, (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42: 2115-23.
3. Li J., Thompson T.D., Miller W., et al. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics. 2008; Vol. 121: e1470-7.
4. Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001-2009. Pediatrics. 2014; 134 (4): X15.
5. Kremer N., Walther A.E., Tiao G.M. Management of hepatoblastoma Curr Opin Pediatr. 2014; 26 (3): 362-9.
6. Meyers R.L., Tiao G., de Ville de Goyet J., Superina R., et al. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014; 26 (1): 29-36.
7. Czauderna P., Lopez-Terrada D., Hiyama E., Haberle B., et al. Hepatoblastoma state of the art Curr Opin Pediatr. 2014; 26 (1): 19-28.
8. McCarville M.B., Kao S.C. Imaging recommendations for malignant liver neoplasms in children. Pediatr Blood Cancer. 2006; 46 (1): 2-7.
9. Roebuck D.J., Aronson D., Clapuyt P., et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007; 37 (2): 123-32.
10. Maibach R., Roebuck D., Brugieres L., et al. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience Eur J Cancer. 2012; 48 (10): 1543-49.
11. Czauderna P., Otte J.-B., Roebuck D.J., von Schweinitz D., et al. Surgical treatment of hepatoblastoma in children. Pediatr Ra- diol. 2006; 36 (3): 187-91.
12. Finegold M.J. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice Med Pediatr Oncol. 2002; 39 (5): 484-6.
13. Schnater J.M., Kohler S.E., Lamers W.H., von Schweinitz D., et al. Where do we stand with hepatoblastoma. Cancer. 2003; 98 (4): 668-78.
14. Czauderna P., Otte J.B., Aronson D.C., Gauthier F., et al. Guidelines for surgical treatment of hepatoblastoma in the modern era - Recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. 2005; 41 (7): 1031-6.
15. Katzenstein H.M., Krailo M.D., Malogolowkin M.H., et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group Intergroup Study. J Clin Oncol. 2002; 20: 2789-97.
16. Finegold M.J., Egler R.A., Goss J.A., et al. Liver tumors: pediatric population. Liver Transpl. 2008; 14 (11): 1545-56.
17. Dicken B.J., Bigam D.L., Lees G.M. Association between surgical margins and long-term outcome in advanced hepatoblastoma. J Pediatr Surg. 2004; 39 (5): 721-5.
18. Fuchs J., Rydzynski J., Hecker H., Mildenberger H., et al. The Influence of Preoperative Chemotherapy and Surgical Technique in the Treatment of Hepatoblastoma - A Report from the German Cooperative Liver Tumour Studies HB 89 and HB 94. Eur J Pediatr Surg. 2002; 12 (4): 255-61.
19. Herzog C.E. Childhood cancers: hepatoblastoma. Oncologist. 2000; 5 (6): 445-53.
20. Hemming A.W., Mekeel K.L., Zendejas I., Kim R.D., et al. Resection of the liver and inferior vena cava for hepatic malignancy. J Am Coll Surg. 2013; 217 (1): 115-24.
21. Otte J.B., Pritchard J., Aronson D.C., Brown J., et al. Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2005; 42 (1): 74-83.